Overview

A Phase 1 Study of GTX-B001 in Healthy Subjets and Patients With Cold Urticaria

Status:
NOT_YET_RECRUITING

Trial end date:
2027-08-01

Target enrollment:

Participant gender:

Summary

This is a first-in-human study aimed at determining the safety of a single dose of GTX-B001 in healthy participants and in people with cold urticaria.

Phase:

PHASE1

Details

Lead Sponsor:

Granular Therapeutics Limited

Treatments:

Saline Solution